WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) reported data from full patient enrollment in the phase 3 SIERRA trial of Iomab-B. The company said the data from the trial showed the potential of Iomab-B in enabling successful bone marrow transplant in patients who cannot typically be transplanted. 100% of patients receiving Iomab-B in the trial were able to proceed to a bone marrow transplant and all achieved engraftment compared to only 18% of patients on the control arm, the company noted.
'We intend to transform bone marrow transplant conditioning with Iomab-B, not only for patients with active, relapsed or refractory AML, but across multiple blood cancer indications. Positive topline data from the SIERRA trial will be a major catalyst in allowing us to achieve that goal and even expand beyond BMT to conditioning for cell and gene therapies,' Sandesh Seth, Actinium's CEO, said.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX